Additive Homeopathy in Cancer Patients

Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Lung Tumors With or Without "add-on" Homeopathy

The investigators aim to investigate the validity of their previous results in a randomized prospective, placebo-controlled, double-blind, multicenter controlled evaluation of questionnaires in patients with advanced malignant tumors. The investigators plan to compare the treatment outcome (quality of life and survival) in tumor patients, receiving standard or "add-on" homeopathic treatment.

The null hypothesis is that "add-on" homeopathic treatment does not create a benefit for cancer patients. In addition the investigators evaluate survival time.

The EORTC-QLQ-C30, SF-36 as well as a VAS scale for subjective well-being will be filled out by the patients.

Inclusion Criteria:

• Informed consent
• Clinical diagnosis of advanced tumor stages of non small-cell lung carcinoma (NSCLC) IIIB, IIIC, IV.

Exclusion Criteria:

• sensitizing mutation of the EGFR gene or translocation of the ALK gene
• refusal to sign informed consent
• pregnancy
• hematological, hepatic, or renal pathology
• coronary heart disease
• history of secondary tumor
• major surgery within 4 weeks prior to study entry
• active infection and symptomatic peripheral neuropathy
• central nervous system metastases unless the metastases were treated and stable
• active autoimmune disease
• use of systemic immunosuppressive treatment
• use of systemic treatment during the previous 2 years
• active interstitial lung disease, or a history of pneumonitis for which glucocorticoids were prescribed
• previous systemic therapy for metastatic disease or previous irradiation
• use of any complementary and/or alternative therapy, including homeopathy other than the research treatment during the trial